Skin Conditions
Photoprotective Effects Of Cannabidiol Against Ultraviolet-B-Induced DNA Damage And Autophagy In Human Keratinocyte Cells And Mouse Skin Tissue
Yanmei Li, Dan Hao, Danfeng Wei, Yue Xiao, Lian Liu, Xiaoxue Li, Lian Wang, Yu Gan, Wei Yan, Bowen Ke, Xian Jiang (October 2022)
The present study investigated the protective effects of CBD against UVB-induced photodamage. CBD protected HaCaT cells from the stimulation of UVB by promoting cell proliferation, alleviating apoptosis, releasing cell cycle arrest, and reducing the DNA damage. CBD also exerted cytoprotective effects by activating autophagy and reducing oxidative stress. In addition, topical application of CBD to the skin of UVB-irradiated mice lowered their photodamage scores, reduced abnormal skin proliferation, and decreased COX-2 expression in skin tissue. These findings, along with evidence reported from other studies, suggest that CBD is a phytocannabinoid with promising beneficial effects for the skin against UV-induced photodamage.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Antioxidant and Anti-Inflammatory Effect of Cannabidiol Contributes to the Decreased Lipid Peroxidation of Keratinocytes of Rat Skin Exposed To UV Radiation
Anna Jastrzab, Iwona Jarocka-Karpowicz, Agnieszka Markowska, Adam Wronski, Agnieszka Gegotek, and Elzbieta Skrzydlewska (February 2021)
There is a great need for compounds with antioxidant and anti-inflammatory properties for protection against UV radiation, which is the most prooxidative physical factor that skin cells are exposed to everyday. Therefore, the aim of the study was to evaluate the mechanism of phytocannabinoid-cannabidiol (CBD) action in vivo on lipid metabolism in keratinocytes of rat skin exposed to UVA/UVB radiation. Our results show that CBD protects keratinocytes against the effects of UVA/UVB radiation by reducing lipid peroxidation products: 4-HNE and 8-isoPGF2α. In addition, CBD significantly increases the level of endocannabinoids, such as anandamide, 2-arachidonylglycerol, and palmitoylethanolamide, and the activation of their receptors CB1/2 or TRPV1. The above changes are due to the protective effect of CBD against the UVA/UVB-induced decrease in the level/activity of superoxide dismutase and the components of the thioredoxin and glutathione systems. CBD also increases the in vivo transcriptional activity of Nrf2 and the expression of its Bach1 inhibitor as well as preventing the UVA/UVB-induced increase in the expression of Nrf2 activators p21, p62, p38, and KAP1 and proinflammatory factors such as NFκB and TNFα. By counteracting oxidative stress and changes in lipid structure in keratinocytes, CBD prevents cellular metabolic disturbances, protecting the epidermis against UV damage.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Positive Effect of Cannabis sativa L. Herb Extracts on Skin Cells and Assessment of Cannabinoid-Based Hydrogels Properties
Martyna Zagórska-Dziok, Tomasz Bukaj, Aleksandra Ziemlewska and Zofia Niziol-Lukaszewska (February 2021)
In addition to the previously known antioxidant properties of the tested extracts, which can have a positive effect on the structure and condition of skin cells, this work also shows other benefits of hemp extracts. Due to the constantly growing popularity of hydrogel preparations in cosmetology and dermatology, the results presented in this work may contribute to the development of new hydrogels containing hemp extracts or individual compounds isolated from Cannabis sativa L. herb. The abilities of inhibiting matrix metalloproteinases, collagenase and elastase, presented for the first time in this work, as well as proven antioxidant properties make these extracts valuable ingredients for the production of a wide range of products that can be used in the treatment and care of the skin. Due to the high demand for preparations that inhibit the aging processes of the skin, the effect of hemp extracts on skin hydration and the possibility of preventing the degradation of collagen and elastin fibers presented here indicates the value of these extracts.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
The Potential Role of Cannabinoids in Dermatology
Tabrez Sheriff, Matthew J. Lin, Danielle Dubin & Hooman Khorasani (October 2019)
Cannabis is increasingly being used world-wide to treat a variety of dermatological conditions. Medicinal cannabis is currently legalized in Canada, 31 states in America and 19 countries in Europe. The authors reviewed the literature on the pharmacology and use of cannabinoids in treating a variety of skin conditions including acne, atopic dermatitis, psoriasis, skin cancer, pruritus, and pain. Cannabinoids have demonstrated anti-inflammatory, antipruritic, anti-ageing, and antimalignancy properties by various mechanisms including interacting with the newly found endocannabinoid system of the skin thereby providing a promising alternative to traditional treatments.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
BTX 1801 Kills Superbugs Without Resistance: World-First Study
Mark Blaskovich (June 2019)
BTX 1801 is a novel topical formulation of cannabidiol which utilises Botanix’s proprietary skin delivery technology, PermetrexTM, to target bacterial infections in the skin. Previous studies conducted by Botanix in collaboration with Dr Blaskovich had demonstrated that cannabidiol has the potential to be a broad-spectrum Gram-Positive antibiotic. These new studies confirm these initial findings and now show the potential for cannabidiol formulated as BTX 1801 to treat serious skin infections.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Cannabis sativa L. Extract and Cannabidiol Inhibit in Vitro Mediators of Skin Inflammation and Wound Injury
Enrico Sangiovanni, Marco Fumagalli, Barbara Pacchetti, Stefano Piazza, Andrea Magnavacca, Saba Khalilpour, Gloria Melzi, Giulia Martinelli and Mario Dell'Agli (June 2019)
Skin inflammatory diseases result from complex events that include dysregulation and abnormal expression of inflammatory mediators or their receptors in skin cells. The present study investigates the potential effect of a Cannabis sativa L. ethanolic extract standardized in cannabidiol as antiinflammatory agent in the skin, unraveling the molecular mechanisms in human keratinocytes and fibroblasts. The extract inhibited the release of mediators of inflammation involved in wound healing and inflammatory processes occurring in the skin.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Cannabinoids in Dermatology: A Scoping Review
Eagleston, Lauren R M; alani, Nazanin Kuseh; Patel; Ravi R, Flaten; Hania K, Dunnick; Cory A, Dellavalle; Robert P (June 2018)
The therapeutic applications of cannabis and cannabinoids are an increasingly conspicuous topic as de-criminalization and legalization of these products continues to expand. A limited number of cannabinoid compounds have been approved for a specific set of conditions. However, the current role of cannabinoids for the treatment of dermatologic conditions remains to be defined. We conducted a review of the current literature to determine the applications of cannabinoids for the therapy of various skin diseases. After conducting our analysis, we found that cannabinoid products have the potential to treat a variety of skin conditions, including acne vulgaris, allergic contact dermatitis, asteatotic dermatitis, atopic dermatitis, hidradenitis suppurativa, Kaposi sarcoma, pruritus, psoriasis, skin cancer, and the cutaneous manifestations of systemic sclerosis.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Self-Initiated Use of Topical Cannabidiol Oil for Epidermolysis Bullosa
Malcolm P. Chelliah BA, Zachary Zinn MD, Phoung Khuu MD, Joyce M. C. Teng, MD, PhD, FAAD (May 2018)
Epidermolysis bullosa is a rare blistering skin disorder that is challenging to manage because skin fragility and repeated wound healing cause itching, pain, limited mobility, and recurrent infections. Cannabidiol, an active cannabinoid found in cannabis, is postulated to have antiinflammatory and analgesic effects. We report 3 cases of self‐initiated topical cannabidiol use in patients with epidermolysis bullosa in an observational study. One patient was weaned completely off oral opioid analgesics. All 3 reported faster wound healing, less blistering, and amelioration of pain with cannabidiol use. Although these results demonstrate promise, further randomized, double‐blind clinical trials are necessary to provide scientific evidence of our observed benefits of cannabidiol for the treatment of epidermolysis bullosa.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.